Piper Sandler Initiates Coverage on Agilent Technologies (NYSE:A)

Research analysts at Piper Sandler began coverage on shares of Agilent Technologies (NYSE:A) in a report issued on Thursday,Benzinga reports. The brokerage set a “neutral” rating and a $150.00 price target on the medical research company’s stock. Piper Sandler’s price objective would indicate a potential upside of 13.74% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Wells Fargo & Company dropped their price objective on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Weiss Ratings raised shares of Agilent Technologies from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, June 2nd. Bank of America raised shares of Agilent Technologies from a “neutral” rating to a “buy” rating and dropped their price objective for the company from $150.00 to $145.00 in a report on Thursday, May 28th. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. Finally, Morgan Stanley dropped their price objective on shares of Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $160.93.

Agilent Technologies Trading Down 2.7%

Shares of Agilent Technologies stock opened at $131.88 on Thursday. The company has a market capitalization of $37.25 billion, a P/E ratio of 26.48, a P/E/G ratio of 2.41 and a beta of 1.26. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.62 and a current ratio of 2.10. The company has a fifty day moving average of $119.63 and a 200 day moving average of $128.00. Agilent Technologies has a fifty-two week low of $108.35 and a fifty-two week high of $160.27.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, beating the consensus estimate of $1.41 by $0.08. Agilent Technologies had a net margin of 19.55% and a return on equity of 24.33%. The business had revenue of $1.84 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the firm earned $1.31 EPS. The business’s revenue was up 10.0% on a year-over-year basis. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. On average, sell-side analysts anticipate that Agilent Technologies will post 5.99 earnings per share for the current fiscal year.

Institutional Trading of Agilent Technologies

Several hedge funds have recently made changes to their positions in A. Norges Bank purchased a new stake in shares of Agilent Technologies during the 4th quarter valued at about $549,158,000. Massachusetts Financial Services Co. MA raised its position in shares of Agilent Technologies by 13.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company’s stock valued at $1,925,064,000 after buying an additional 1,713,216 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Agilent Technologies by 424.1% during the 2nd quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after buying an additional 1,652,244 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Agilent Technologies by 132.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after buying an additional 1,340,161 shares in the last quarter. Finally, Balyasny Asset Management L.P. raised its position in shares of Agilent Technologies by 192.0% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,412,535 shares of the medical research company’s stock valued at $192,204,000 after buying an additional 928,821 shares in the last quarter. 87.41% of the stock is currently owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett?Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.